Trials / Recruiting
RecruitingNCT05701709
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
An Open-Label, Single-Arm, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of SHR-A2102 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 395 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study was designed to evaluate the efficacy, safety, and pharmacokinetics of SHR2102 in patients with advanced solid tumors. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of SHR-A2102 in phase II study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A2102 | SHR-A2102 was given intravenously. Patients may continue to use SHR-A2102 until disease progression or unacceptable toxicity occurs. |
Timeline
- Start date
- 2023-04-06
- Primary completion
- 2025-08-31
- Completion
- 2025-08-31
- First posted
- 2023-01-27
- Last updated
- 2025-07-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05701709. Inclusion in this directory is not an endorsement.